Department of Otolaryngology - Head and Neck Surgery, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9035, USA.
Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609.
Allergic rhinitis is an IgE-mediated condition that produces inflammation of the mucosa of the nose, paranasal sinuses and, frequently, of the ocular conjunctiva. Allergic rhinitis causes a significant disease burden in terms of quality of life, lost productivity and medical treatment costs. One of the newest treatments approved by the FDA is Patanase (olopatadine hydrochloride) Nasal Spray, 665 microg/spray (OLO). Olopatadine is an antihistamine with selective H(1)-receptor antagonist activity.
This review details the basic and clinical research on the olopatadine molecule and OLO nasal spray from 1996 to the present day.
The reader will gain a better understanding of the pharmacology of OLO nasal spray, the clinical trial data that have established the efficacy of OLO nasal spray and the overall role of OLO nasal spray in the management of allergic rhinitis.
Olopatadine nasal spray is one of the newest treatments approved by the FDA for the management of allergic rhinitis. OLO has a rapid onset of action, efficacy comparable to intranasal steroid sprays and is approved for seasonal allergic rhinitis in patients aged > or = 6 years.
变应性鼻炎是一种 IgE 介导的疾病，会导致鼻黏膜、副鼻窦和眼部结膜的炎症。变应性鼻炎会导致生活质量下降、生产力下降和医疗费用增加等方面的显著疾病负担。美国食品和药物管理局 (FDA) 最近批准的一种新疗法是帕坦塞（盐酸奥洛他定）鼻喷雾剂，每喷 665 微克（OLO）。奥洛他定是一种具有选择性 H1 受体拮抗剂活性的抗组胺药。
本篇综述详细介绍了奥洛他定分子和 OLO 鼻喷雾剂的基础和临床研究，从 1996 年至今。
读者将更好地了解 OLO 鼻喷雾剂的药理学、已确立 OLO 鼻喷雾剂疗效的临床试验数据以及 OLO 鼻喷雾剂在变应性鼻炎管理中的整体作用。
奥洛他定鼻喷雾剂是美国食品和药物管理局最近批准的治疗变应性鼻炎的新疗法之一。OLO 起效迅速，疗效可与鼻内类固醇喷雾剂媲美，适用于年龄大于或等于 6 岁的季节性变应性鼻炎患者。
Zotero 插件